Acri Capital Acquisition Corporation Announces Confidential Submission of Draft Registration Statement on Form S-4 and Extension of the Deadline for an Initial Business Combination
April 10, 2024 16:30 ET
|
Acri Capital Acquisition Corporation
Austin, Texas, April 10, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in relation to its...
Acri Capital Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination
March 13, 2024 16:05 ET
|
Acri Capital Acquisition Corporation
Austin, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend...
Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, Inc.; Troika Media Group, Inc.; Impel Pharmaceuticals Inc.; Fresh Tracks Therapeutics, Inc.; and Near Intelligence, Inc. from The Nasdaq Stock Market
December 26, 2023 16:05 ET
|
Nasdaq, Inc.
NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc. SmileDirectClub, Inc.’s securities were suspended on...
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
October 16, 2023 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Global Antibiotic Resistance Markets, 2023-2027: Beyond Antibiotics - Exploring Cutting-Edge Trends in AMR Solutions
October 05, 2023 06:43 ET
|
Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
September 19, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
41% of U.S. Workers Say They are Most Productive Outside of 9-5 Work Hours, According to Research from Fiverr
September 19, 2023 08:00 ET
|
Fiverr International Ltd.
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Fiverr International Ltd. (NYSE: FVRR), the company that is revolutionizing how the world works together, has compiled findings from a study exploring...
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
September 18, 2023 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
August 28, 2023 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...